Muñoz Martín A J, García Alfonso P, Rupérez Blanco A B, Pérez Ramírez S, Blanco Codesido M, Martín Jiménez M
Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain,
Clin Transl Oncol. 2014 Oct;16(10):927-30. doi: 10.1007/s12094-014-1165-y. Epub 2014 Mar 19.
To evaluate the incidence of venous thromboembolism (VTE) in ambulatory pancreas cancer patients receiving chemotherapy and analyze Khorana's predictive model of chemotherapy-associated thrombosis.
METHODS/PATIENTS: We performed a retrospective review to determine the incidence of VTE in the gastrointestinal cancer unit of our center. Between 2008 and 2011, 84 consecutives patients diagnosed with pancreas adenocarcinoma were identified and included in the analysis. Pancreatic neuroendocrine tumors were excluded.
Thirty patients experienced VTE (35.7 %) and 66 % of the events were diagnosed during the first 6 months after diagnosis. Khorana's score: 33.3 % of the intermediate category patients developed a venous thromboembolic event and 37.5 % in the high-risk category.
The high incidence of VTE observed in this study is consistent with prior reports. Specific predictive model for chemotherapy-associated thrombosis in pancreatic cancer must be investigated.
评估接受化疗的门诊胰腺癌患者静脉血栓栓塞（VTE）的发生率，并分析霍纳纳化疗相关血栓形成预测模型。
方法/患者：我们进行了一项回顾性研究，以确定我院胃肠癌科室VTE的发生率。2008年至2011年期间，连续84例被诊断为胰腺腺癌的患者被纳入分析，胰腺神经内分泌肿瘤患者被排除。
30例患者发生VTE（35.7%），66%的事件在诊断后的前6个月内被诊断出来。霍纳纳评分：中危组患者发生静脉血栓栓塞事件的比例为33.3%，高危组为37.5%。
本研究中观察到的VTE高发生率与先前报告一致。必须研究针对胰腺癌化疗相关血栓形成的特定预测模型。
